Value-based medicine: Evidence-based medicine and beyond

References

• Case KE, Fair RC. Principles of economics. 4th ed. Upper Saddle River, NJ: Prentice Hall, Inc. 1996; 1–133.
   Google Scholar
• National Health Expenditures. Aggregate and per capita amounts, percent distribution, and average annual percent growth, by source of funds. Select calendar years 1980–2001. From the Internet, www.cms.hhs.gov, cited 1-20–03.
   Google Scholar
• National healthcare expenditures projections: 2001–2011. From the Internet, www.cms.hhs.gov, cited 1-20–03.
   Google Scholar
• Brown MM, Brown GC, Sharma S, Hollands H, Smith A. Physician manpower and health care expenditures in the United States: a thirty year perspective. J Healthcare Finance. 2001(4);27:55–64.
   Google Scholar
• World Health Organization. Report 2000. From the Internet, www. who.int/health-systems-performance/ whrz000.htm, cited 4-3–03.
   Google Scholar
• Brown GC, Brown MM, Sharma S, Tasman W, Brown H. Costeffectiveness treatment for threshold retinopathy of prematurity. Pediatrics. 1999;104(4):e47.
   Google Scholar
• Brown GC, Brown MM, Sharma S, Busbee B, Brown H. Incremental cost-effectiveness of laser photocoagulation for choroidal neovascularization associated with histoplasmosis. Retina. 2000;20: 331–337.
   Google Scholar
• Brown GC, Brown MM, Sharma S. Incremental cost-effectiveness of laser therapy for subfoveal choroidal neovascularization. Ophthalmology. 2000;107:1374–1380.
   Google Scholar
• Smith A, Brown GC. Cost-effectiveness of treatment for threshold retinopathy of prematurity. Br J Ophthalmol. 2000;54:794–798.
   Web of Science ®Google Scholar
• Brown GC, Brown MM, Sharma S, Busbee B, Brown H. Incremental cost-effectiveness of therapeutic interventions for branch retinal vein occlusion. Ophthalmic Epidemiol. 2002;9:I–10.
   Google Scholar
• Sharma S, Brown GC, Brown MM, Hollands H, Shah GK. The cost-effectiveness of photodynamic therapy for fellow eyes with subfoveal choroidal neovascularization secondary to age-related macular degeneration. Ophthalmology. 2001;108:2051–2059.
   Google Scholar
• Busbee B, Brown MM, Brown GC, Sharma S. Incremental cost-effectiveness of initial cataract surgery. Ophthalmology. 2002;109: 606–612.
   PubMed Web of Science ®Google Scholar
• Sharma S, Brown GC, Brown MM, Sharma SM, Hollands H, Brown H, Shah G. The cost-effectiveness of grid laser photocoagulation for the treatment of diabetic macular edema: results of a patient-based cost-utility analysis. Curr Opin Ophthalmol. 200011: 175–179.
   Google Scholar
• Brown GC, Brown MM, Sharma S, Busbee B. A cost-utility analysis of interventions for proliferative vitreoretinopathy. Am J Ophthalmol. 2002;133:365.
   PubMed Web of Science ®Google Scholar
• Brown GC, Brown MM. Is prophylactic PRP in ischemic CRVO a good idea? Rev Ophthalmol. 2000;7:106,108,111.
   Google Scholar
• Sharma S, Hollands H, Brown GC, Brown MM, Shah G, Sharma SM. The cost-effectiveness of early vitrectomy for the treatment of vitreous hemorrhage in diabetic retinopathy. Curr Opin Ophthalmol. 2001;12:230–234.
   PubMed Web of Science ®Google Scholar
• Javitt JC, Canner JK, Sommer A. Cost effectiveness of current approaches to the control of retinopathy in type I diabetics. Ophthalmology. 1989;96:255–264.
   Google Scholar
• Javitt JC, Canner JK, Frank RG, et al. Detecting and treating retinopathy in patients with type I diabetes mellitus. A health policy model. Ophthalmology. 199o:97:483–494.
   Google Scholar
• Javitt JC, Aiello LP. Cost-effectiveness of detecting and treating diabetic retinopathy. Ann Intern Med. 1996;124:164–169.
   PubMed Web of Science ®Google Scholar
• Brown GC, Brown MM, Sharma S. Health care in the 21st century. Evidence-based medicine, patient preference-based quality and cost-effectiveness. Qual Manage Health Care. 2000;19: 23–31.
   Google Scholar
• Brown GC, Brown MM, Sharma S, Brown H, Gozum M, Denton P. Quality of life associated with diabetes mellitus in an adult population. J Diab Its Complic. 2000;14:18–24.
   PubMed Web of Science ®Google Scholar
• Drummond ME O'Brien B, Stoddart GL, Torrance GW. Methods for the economic evaluation of health care programmes. 2nd ed. New York: Oxford University Press, 1999; 139–199.
   Google Scholar
• Stein J, Brown GC, Brown MM, Sharma S, Hollands, Stein HD. The quality of life of patients with hypertension. J Clin Hypertens. 2002;4:4181–4188.
   Google Scholar
• Sharma S. Levels of evidence. Evidence-Based Eye Care. 2002;3: 121–122.
   Google Scholar
• Sackett DL, Straus SE, Richardson WS, Rosenberg W, Haynes RB. Evidence-based medicine. How to practice and teach EBM. 2nd ed. Philadelphia: Churchill Livingstone, 2000; 95–153.
   Google Scholar
• Yaphe J, Edman R, Knishkowy B, Herman J. The association between funding by commercial interests and study outcome in randomized controlled drug trials. Fam Pract. 2001;18:565–568.
   PubMed Web of Science ®Google Scholar
• Kjaergard LL, Als-Nielsen B. Association between competing interests and authors' conclusions. Epidemiological study of randomized clinical trials published in the BMJ. Br Med J. 2002;325:249.
   PubMedGoogle Scholar
• Briggs AH, O'Brien BJ. The death of cost-minimization analysis? Health Econ. 2001;10:179–184.
   Google Scholar
• Brown MM, Brown GC, Sharma S, Landy J. Health care economic analyses and value-based medicine. Surv Ophthalmol. 2003;48:204–223.
   PubMed Web of Science ®Google Scholar
• Cresswell PA, Allen ED, Tompkinson J, et al. Cost effectiveness of a single functioning treatment center for cataract surgery. J Cataract Refract Surg. 1996;22:940–946.
   PubMed Web of Science ®Google Scholar
• Membreno J, Brown MM, Brown GC, Sharma S, Beauchamp G. A cost-utility analysis of therapy for amblyopia. Ophthalmology. 2002;109:2265-227 I.
   Google Scholar
• Membreno J, Brown MM, Brown GC, Sharma S, Beauchamp G. Letter to the editor on 'A cost-utility analysis of therapy for amblyopia'. Ophthalmology [In press12003.
   Google Scholar
• Tengs TO, Adams ME, Pliskin JP, et al. Five-hundred life-saving interventions and their cost-effectiveness. Risk Anal. 1995;15: 369–390.
   PubMed Web of Science ®Google Scholar
• Gold MR, Patrick DL, Torrance GW, Fryback DG, Hadorn DC, Kamlet MS, Daniels N, Weinstein MC. Identifying and valuing outcomes. In: Gold ME, Siegel JE, Russell LB, Weinstein MC, editors. Cost-effectiveness in health and medicine. New York: Oxford University Press, 1996; 82–134.
   Google Scholar
• Weinstein MC, Stasson WB. Foundations of cost-effective analysis for health and medical practice. N Engl J Med. 1977;296: 716–721.
   PubMed Web of Science ®Google Scholar
• Edelman D, Williams GR, Rothman M, Samsa GP. A comparison of three health status measures in primary care patients. J Gen Intern Med. 1999;14:759–762.
   PubMed Web of Science ®Google Scholar
• National Eye Institute Visual Functioning Questionnaire - 25 (VFQ-25). From the Internet@ www.neimih.gov, cited April 2,2001.
   Google Scholar
• Redelmeier DA, Detsky A. A clinician's guide to utility measurement. Med Decis Making. 1995;22:271–281.
   Google Scholar
• Brown GC. Vision and quality of life. Trans Am Ophthalmol Soc. 1999;97:473–512.
   PubMedGoogle Scholar
• Brown GC, Brown MM, Sharma S, Kistler J. Utility values associated with age-related macular degeneration. Arch Ophthalmol. 2000118: 47–51.
   Google Scholar
• Brown MM, Brown GC, Sharma S, Shah G. Utility values and diabetic retinopathy. Am J Ophthalmol. 1999;128:324–330.
   PubMed Web of Science ®Google Scholar
• Brown MM, Brown GC, Sharma S, et al. Utility values associated with blindness in an adult population. Br J Ophthalmol. 2001;85:327–331.
   PubMed Web of Science ®Google Scholar
• Brown MM, Brown GC, Sharma S, Landy J. Quality of life with visual acuity loss from diabetic retinopathy and age-related macular degeneration. Arch Ophthalmol. 2002;120:481–484.
   PubMedGoogle Scholar
• Froberg D, Kane RL. Methodology for measuring health state preferences. II. Scaling methods. J Clth Epidemiol. 1989;42:459–471.
   Google Scholar
• Rosner B. Fundamentals of biostatistics. 5th ed. Pacific Grove, CA: Duxbury Thomson Learning, 2000; 562–565.
   Google Scholar
• Brown GC, Brown MM, Sharma S. Difference between ophthalmologist and patient perceptions of quality-of-life associated with age-related macular degeneration. Can J Ophthalmol. 2000;35:27–32.
   Google Scholar
• Stein J, Brown GC, Brown MM, Sharma S, Hollands, Stein HD. The quality of life of patients with hypertension. J Clin Hypertens. 2002;4:181–188.
   Google Scholar
• Landy J, Stein JD, Brown GC, Brown MM, Sharma S. Patient, community and clinician perceptions of the quality of life associated with diabetes mellitus. Med Sci Monit. 2002;8:543–548.
   Google Scholar
• Hollands H, Lam M, Pater J, Albiani D, Brown GC, Brown MM, Cruess AF, Sharma S. Reliability of the time trade-off technique of utility assessment in patients with retinal disease. Can J Ophthalmol. 2001;36: 202–209.
   PubMed Web of Science ®Google Scholar
• Brown GC, Brown MM, Sharma S, Beauchamp G, Hollands H. The reproducibility of ophthalmic utility values. Trans Am Ophthalmol Soc. 2001;99:71–76.
   Google Scholar
• Brown MM, Brown GC, Sharma S, Hollands H. Quality-of-life and systemic comorbidities in patients with ophthalmic disease. Br J Ophthalmol. 2002;86:8-II.
   Google Scholar
• Sharma S, Brown GC, Brown MM, Hollands H, Robbins R, Shah G. Validity of the time trade-off and standard gamble methods of utility assessment in retinal patients. Br J Ophthalmol. 2002;86:493–496.
   PubMed Web of Science ®Google Scholar
• Klarman H, Francis J, Rosenthal G. Cost-effectiveness applied to the treatment of chronic renal disease. Med Care. 1968;6:48–55.
   Google Scholar
• Macular Photocoagulation Study Group. Argon laser photocoagulation for neovascular maculopathy: five-year results from randomized clinical trials. Arch Ophthalmol. 1991;109:1109–1114.
   PubMed Web of Science ®Google Scholar
• Heudebert GR, Centor RM, Klapow JC, et al. What is heartburn worth? A cost-utility analysis of management strategies. J Gen Intern Med. 2000;15:175–182.
   PubMed Web of Science ®Google Scholar
• Laupacis A, Feeny D, Detsky AS, Tugwell PX. How attractive does a new technology have to be to warrant adoption and utilization. Tentative guidelines for using clinical and economic evaluations. Can Med Assoc J. 1992;146:473–481.
   Google Scholar
• Siegel JE, Weinstein MC, Russell LB, Gold MR. Recommendations for reporting cost-effectiveness analyses. Panel on Cost-Effectiveness in Health and Medicine. J Am Med Assoc. 1996; 276:1339–1341.
   PubMed Web of Science ®Google Scholar
• Sharma S, Oliver A, Bakal J, Hollands H, Brown GC, Brown MM. Utilities associated with diabetic retinopathy. Results from a Canadian sample. Br J Ophthalmol. 2003;87:259–261.
   PubMed Web of Science ®Google Scholar
• Brown E, Fitzner K: Cost-effectiveness and coverage policy. Physician Exec. 1999;25:75–77.
   PubMedGoogle Scholar
• Cohen HE, editor. 2002 Drug Topics RED BOOK. Montvale, NJ: Thomson Medical Economics, 2002.
   Google Scholar